Sinoma Science & Technology stock
002080.SZSHZSinoma Science & Technology Co.,Ltd., Basic MaterialsISIN CNE000001P78
42Score 42 out of 100, Weak
Price and trend
38 / 100
Price history
+8.3% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 34% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 64% below its 52-week high. Largest decline in 19 years: 79% (September 2021 to September 2024).
Chart figures for advanced users
- SMA 50$6.98
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.95
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.45
- The lowest closing price of the last twelve months.
- Resistance$14.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sinoma Science & Technology Co.,Ltd. belongs to the Chemicals (Specialty) industry (China) and, with a market value of $9.2B, is number 34 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.51B (up 25.5% year on year) and earnings of $272.5M (up 103.8%).
- MEQIRI Score 42 out of 100 (Weak): rank 377 of 467 in Basic Materials, median 58.
Show more
- The P/E is 27.3 (Chemicals (Specialty) median 20.2, own median of recent years 16.3).
- Our model puts fair value at $1.94, with the price 175% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.
Weaknesses
- Above fair valuePrice 175% above the fair value of $1.94.Valuation 49
- Negative free cash flowFree cash flow −$17.41M over the last 12 months.Fundamentals 47
- Margin fallingOperating margin 6.9%, average of the prior years 12.2% (to 2024).Profitability 43
The score is held back by capital allocation and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $1.29 and expensive above $3.88 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $0.04 (cash-flow model) and $3.85 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.7%. At 8.7% the fair value would be $1.94, at 6.7% it would be $1.95.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (20.2).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 18.3% on the twelve months before. Revenue has grown strongly since 2006, at around 22% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 18%, operating 7%, net 6%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 12 Mar 2027in 120 days
- Last reported
- 23 Oct 2026EPS reported $0.06 (expected $0.05)above expectations
Analyst estimates
- Earnings per share
- $0.25−9.5%
- Revenue
- $5.31B−2.2%
- Earnings per share
- $0.42−6.7%
- Revenue
- $6B−2.0%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Sinoma Science & Technology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 42
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- Grace Fabric Technology603256.SS $11.14B62
- Evonik IndustriesEVK.DE $10.87B61
- Solstice Advanced MaterialsSOLS $10.56B63
- BrenntagBNR.DE $9.55B56
- Tianqi Lithium002466.SZ $8.78B58
- Guangzhou Tinci Materials Technology002709.SZ $8.51B69
- Element SolutionsESI $8.26B54
- WestlakeWLK $8.17B39
ETFs that hold Sinoma Science & Technology
Held by 37 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers MSCI China A UCITS ETF 1CDBX9 | 0.14% | 0.35% | €106.6M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.09% | 0.65% | €10.8M |
| Amundi MSCI New Energy UCITS ETF DistLYM9 | 0.06% | 0.60% | €956.11M |
Show 5 more
| Amundi MSCI China ESG Selection Extra UCITS ETF AccLCHI | 0.04% | 0.65% | €473.19M |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.03% | 0.30% | €134.65M |
| iShares MSCI China UCITS ETFICGA | 0.02% | 0.28% | €2.22B |
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.3B |
| Amundi MSCI Emerging Markets ESG Selection UCITS ETF DR (C)SADM | 0.01% | 0.18% | €1.02B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.